Authors
Chee Khoon Lee, Chris Brown, Richard J Gralla, Vera Hirsh, Sumitra Thongprasert, Chun-Ming Tsai, Eng Huat Tan, James Chung-Man Ho, Da Tong Chu, Adel Zaatar, Jemela Anne Osorio Sanchez, Vu Van Vu, Joseph Siu Kie Au, Akira Inoue, Siow Ming Lee, Val Gebski, James Chih-Hsin Yang
Publication date
2013/5/1
Source
Journal of the National Cancer Institute
Volume
105
Issue
9
Pages
595-605
Publisher
Oxford University Press
Description
Background
The epidermal growth factor receptor (EGFR) signaling pathway is crucial for regulating tumorigenesis and cell survival and may be important in the development and progression of non–small cell lung cancer (NSCLC). We examined the impact of EGFR–tyrosine kinase inhibitors (TKIs) on progression-free survival (PFS) and overall survival (OS) in advanced NSCLC patients with and without EGFR mutations.
Methods
Randomized trials that compared EGFR-TKIs monotherapy or combination EGFR-TKIs-chemotherapy with chemotherapy or placebo were included. We used published hazard ratios (HRs), if available, or derived treatment estimates from other survival data. Pooled estimates of treatment efficacy of EGFR-TKIs for the EGFR mutation–positive (EGFRmut+) and EGFR mutation–negative (EGFRmut–) subgroups were calculated with the fixed-effects …
Scholar articles
CK Lee, C Brown, RJ Gralla, V Hirsh, S Thongprasert… - Journal of the National Cancer Institute, 2013